| Literature DB >> 34335836 |
Mohammad Zubair Alam1,2, Mohd Sajjad Ahmad Khan3.
Abstract
Candida spp are capable of infecting both normal and immunocompromised individuals. More recently, Candida infections have spread considerably in healthcare settings, especially in intensive care units, where it is the most frequently encountered pathogen. Candida albicans is the commonest species encountered, although infections by non-albicans species have also risen in the past few years. The pathogenicity of Candida is credited to its aptitude to change between yeast and hyphal modes of growth. Candida spp produce biofilms on synthetic materials that protect them and facilitate drug resistance and act as a source for chronic and recurrent infections. Primarily, azoles antifungal agents are utilized to treat Candida infection that targets the ergosterol synthesis pathway in the cell wall. The development of antifungal resistance in Candida species is a major reason for treatment failure, and hence, there is a need to develop newer antifungal molecules and/or modifications of existing antifungals to make them more effective and less toxic. This has led researchers to oversee the plants to discover newer antimicrobials. Middle Eastern countries are well known for their landscape ranging from dry and sandy deserts to snow-capped mountains. However, they comprise enormous plant diversity with over 20,000 different species showing various types of bioactivities, such as anticancer, antidiabetic, and antimicrobial activities. Especially, the antifungal potential of these phytoproducts could be exploited in the clinical setting for therapy. The present review examines some of the promising alternative natural compounds that have been tested and found effective in treating Candida infections in vitro in some Middle Eastern countries.Entities:
Year: 2021 PMID: 34335836 PMCID: PMC8298167 DOI: 10.1155/2021/6694876
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Significance of ethnomedicinal use of plants from the Middle East and Arabian Peninsula (adapted from Aati et al. [24]).
Plants or their extracts reported from Middle Eastern countries with anti-Candida activities.
| Country | Plant or extract | Effects on | Reference |
|---|---|---|---|
| Saudi ArabiaUAE |
| EO highly inhibitory; IZ = 43 mm | [ |
|
| EO highly inhibitory; IZ = 45 mm | ||
|
| EO highly inhibitory; IZ = 30 mm | ||
|
| EO highly inhibitory; IZ = 39 mm | ||
|
| EO highly inhibitory; IZ = 42 mm | ||
|
| EO moderately inhibitory; IZ = 17 mm | ||
|
| EO no effect on growth inhibition | ||
|
| EE inhibitory, IZ = 22 mm; % growth inhibition significant; MIC = 10 | [ | |
|
| EE inhibitory, IZ = 17 mm; % growth inhibition significant; 10 | ||
|
| EE inhibitory, IZ = 17 mm; % growth inhibition significant; 25 | ||
|
| EE moderately inhibitory, IZ = 11 mm; % growth inhibition significant; 50 | ||
|
| EO and ME eradicated | [ | |
|
| Nanoconjugates were having strong anti- | [ | |
| Honey (four types Markh, Manuka, Qatad, Sider) | Markh and Manuka honey completely inhibited | [ | |
| Taif rose oil | Complete inhibition of | ||
|
| DEE IZ = 19 mm ( | [ | |
| EAE IZ = 21 mm ( | |||
| ME IZ = 16 mm ( | |||
| HE IZ = 19 mm ( | |||
|
| EE meswak extract (20%) was highly inhibitory against | [ | |
|
| EO strongly active against | [ | |
|
| DCME MIC against | [ | |
| 3′, 4′, 5, 7-Tetramethoxyflavone | 90% of | ||
|
| Ethanol and chloroform extracts exhibited strong anti- | [ | |
|
| EO was active against | [ | |
|
| Ethyl acetate extract contained isopimpinellin and exhibited antibiofilm activity | [ | |
|
| |||
| Turkey | Propolis (19 different types) | MIC ranged between 128 and 512 | [ |
|
| Strong anti- | [ | |
|
| EO had strong inhibitory effect against | [ | |
|
| ME exhibited better antimicrobial activity than EO; 80% inhibition in adhesion of | [ | |
|
| PEE alkaloid aporphine highly effective against | [ | |
|
| |||
| Egypt |
| CHE was highly inhibitory for | [ |
|
| EOs from these plants exhibited strong anti- | [ | |
| Henna, pomegranate, myrrh | 15% extracts (individual and mix) were comparable to commercial gentamycin in inhibiting | [ | |
|
| AE strong activity against | [ | |
|
| |||
|
| |||
| Yemen |
| ME exhibited considerable antifungal activities | [ |
|
| VO was more effective to Gram-positive than Gram-negative bacteria. VO exhibited strong activity against | [ | |
|
| |||
| Jordan |
| EO was moderately effective on | [ |
|
| AE was highly inhibitory against | [ | |
|
| BE was highly inhibitory against | ||
|
| EO was inhibitory to | [ | |
|
| EO of | [ | |
|
| |||
| Israel and Palestine |
| Various organic extracts exhibited an MIC of 500 | [ |
|
| Naturally occurring naphthoquinones (droserone and 5-O-methyldroserone) were highly effective against | [ | |
|
| EO exhibited strong inhibitory activity against | [ | |
|
| |||
| Iran |
| Significantly better anti- | [ |
|
| Vaginal cream containing | [ | |
|
| The EO from wildly growing | [ | |
|
| Highly effective against | [ | |
Note. IZ = inhibition zone; EO = essential oil; AE = aqueous extract; HE = hexane extract; BE = butanol extract; CHE = chloroform extract; ME = methanol extract; EE = ethanol extract; EAE = ethyl acetate extract; DCME = dichloromethane extract; DEE = diethylether extract; PEE = petroleum ether; and VO = volatile oil.